In the lung cancer setting, the PIR test (Resistant vs. Not Resistant) was a significant predictor of survival when adjusted for ECOG performance status, smoking history, histology, and PD-L1 expression (p = 0.030) [67]. This evidence concerns the gene CD274 and lung carcinoma.